H.C. Wainwright Initiates Coverage on Neurocrine Biosciences(NASDAQ:NBIX). The shares have been rated Buy. The rating by H.C. Wainwright was issued on Jun 29, 2016.
In a different note, BMO Capital said it Initiates Coverage on Neurocrine Biosciences, according to a research note issued on Apr 7, 2016. The shares have been rated ‘Outperform’ by the firm.
Neurocrine Biosciences (NBIX) shares turned negative on Fridays trading session with the shares closing down -0.16 points or -0.35% at a volume of 9,57,698. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $45.79. The peak price level was also seen at $45.79 while the days lowest was $44.69. Finally the shares closed at $45.29. The 52-week high of the shares is $58.46 while the 52-week low is $31.25. According to the latest information available, the market cap of the company is $3,925 M.
Neurocrine Biosciences(NBIX) last announced its earnings results on May 5, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $15.00M. Analysts had an estimated revenue of $15.43M. Earnings per share were $-0.22. Analysts had estimated an EPS of $-0.29.
Several Insider Transactions has been reported to the SEC. On Jun 2, 2016, Malcolm Lloyd-smith (Chief Regulatory Officer) sold 9,000 shares at $50.00 per share price.Also, On Jun 2, 2016, Christopher Flint Obrien (Chief Medical Officer) sold 12,500 shares at $50.00 per share price.On May 26, 2016, Richard F Pops (director) sold 15,000 shares at $46.72 per share price, according to the Form-4 filing with the securities and exchange commission.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.